Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

About this update from Iridex Corporation

[{"type":"image","alt":"IRIDEX Corporation","displaySize":"","headline":null,"caption":"IRIDEX Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r51WXqBBd3BbgLab_DBobg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250","width":300,"height":90}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients presenting with severe diabetic macular edema (DME).","length":640,"tagName":"p"},{"type":"text","content":"Led by Principal Investigator Professor Noemi Lois at Queen’s University Belfast, the study is designed to include at least 20 clinical sites and enroll 264 participants across the United Kingdom with severe DME, defined as having central retinal subfield thickness (CRT) or ≥400 μm once CRT goes below 400μm. The trial is intended to develop a blueprint for the implementation of the new treatment pathway (i.e., adding subthreshold MicroPulse laser only when the CRT is <400μm following anti-VEGFs) into clinical practice, if this is shown to be beneficial to people with DME.","length":586,"tagName":"p"},{"type":"text","content":"“Current treatment for DME relies heavily on frequent anti-VEGF injections, which are not only expensive and burdensome to patients and healthcare systems but can also lead to patient anxiety along with having potential sight-threatening complications,” said Professor Lois. “DAME may transform the care of people living with diabetes and DME if the trial shows that continuing with subthreshold MicroPulse laser, once the DME has improved following anti-VEGFs, is equivalent in terms of visual outcomes to...

More updates from Iridex Corporation